Deutsche Bank lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 750 from DKK 815 and keeps a Hold rating on the shares.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application
- Zealand Pharma says FDA issues CRL for glepaglutide NDA
- Zealand Pharma announces first participant enrolled in ZUPREME-1
- Zealand Pharma upgraded to Hold from Sell at Danske Bank
- Zealand Pharma initiated with an Overweight at JPMorgan